Referred to the House Health Care & Wellness Committee on January 23, 2017
Substitute offered in the House on February 17, 2017
Requires issuers and drug manufacturers to report certain prescription drug pricing data to a data organization contracted by the Office of Financial Management (OFM).
Referred to the House Appropriations Committee on February 17, 2017
Substitute offered in the House on February 24, 2017
The Office of Financial Management (OFM) must use a competitive procurement process to select a data organization to collect, verify, and summarize prescription drug pricing data provided by issuers and drug manufacturers. "Prescription drugs" include generic, brand name, and specialty drugs, as well as biological products.